



UvA-DARE (Digital Academic Repository)

Optimising quality of platelet transfusions

Kostelijk, E.H.

Publication date
2000

[Link to publication](#)

Citation for published version (APA):

Kostelijk, E. H. (2000). *Optimising quality of platelet transfusions*. [Thesis, externally prepared, Universiteit van Amsterdam].

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

REFERENCES

1. Verstraete M, Vermeylen J: Cellular, chemical and rheological factors in thrombosis and fibrinolysis; in Verstraete, M. and Vermeylen, J. (ed): *Thrombosis*. Oxford, Pergamon press, 1984, vol 1-54.
2. Gmür J, Burger J, Schanz U, Fehr J, Schaffner A: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. *Lancet* 1991; 338:1223-1226
3. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP: Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/ μ l versus 20,000/ μ l. *J. Clin. Oncol.* 1997; 15:1143-1149
4. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. *New Engl. J. Med.* 1997; 337:1870-1875
5. Hutton RA, Laffan MA, Tuddenham EGD: Normal haemostasis; in Hoffbrand, A. V., Lewis, S. M., and Tuddenham, E. G. D. (ed): *Postgraduate Haematology*. Oxford, Butterworth Heinemann, 1999, pp. 550-580.
6. Ellis MH, Avraham H, Groopman JE: The regulation of megakaryocytopoiesis. *Blood reviews* 1995; 9:1-6
7. Roth GJ: Platelets and blood vessels: the adhesion event. *Immunol. Today* 1992; 13:100-105
8. Sixma JJ, de Groot PG: Platelet adhesion to the vessel wall; in Smit Sibinga, C. Th, Das, P. C., and Mannucci, P. M. (ed): *Coagulation and blood transfusion*. Dordrecht/Boston/London, Kluwer Academic Publishers, 1991, pp. 83-91.
9. Sixma JJ, van Zanten GH, Huizinga EG, van der Plas M, Verkley M, Wu Y-P, Gros P, De Groot PG: Platelet adhesion to collagen: an update. *Thrombos. Haemostas.* 1997; 78:434-438
10. Sixma JJ, van Zanten GH, Saelman EUM, Verkley M, Lankhof H, Nieuwenhuis HK, De Groot PG: Platelet adhesion to Collagen. *Thrombos. Haemostas.* 1995; 74:454-459
11. Boon GD: An overview of Hemostasis. *Tox. Pathol.* 1993; 21:170-179
12. Wachtfogel YT, DeLa Cadena RA, Colman RW: Structural biology, cellular interactions and pathophysiology of the contact system. *Thromb. Res.* 1993; 72:1-21
13. Spraggon G, Everse SJ, Doolittle RF: Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. *Nature* 1997; 389:455-462
14. Vischer UM, Wollheim CB: Purine nucleotides induce regulated secretion of von Willebrand factor: involvement of cytosolic Ca^{2+} and cyclic adenosine monophosphate-dependent signalling in endothelial exocytosis. *Blood* 1998; 91:118-127
15. Preissner KT, Potzsch B: Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitronectin. *Histol. Histopathol.* 1995; 10:239-251
16. Vischer UM, Wagner DD: CD63 is a component of Weibel-Palade bodies of human endothelial cells. *Blood* 1993; 15:1184-1191
17. Wagner DD, Bonfanti R: von Willebrand factor and the endothelium. *Mayo Clin Proc* 1991; 66:621-627

18. Savage B, Almus-Jacobs F, Ruggeri ZM: Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. *Cell* 1998; 94:657-666
19. Bombeli T, Schwartz BR, Harlan JM: Adhesion of activated platelets to endothelial cells: evidence for a GPIIb/IIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), α v β 3 integrin, and GPIIb/IIIa. *J. Exp. Med.* 1998; 187:329-339
20. Polanowska-Grabowska R, Simon CGJ, Gear AR: Platelet adhesion to collagen type I, collagen type IV, von Willebrand factor, fibronectin, laminin and fibrinogen: rapid kinetics under shear. *Thrombos. Haemostas.* 1999; 81:118-123
21. Harrison P, Cramer EM: Platelet α -granules. *Blood Rev.* 1993; 7:52-62
22. Barnes MJ, Knight CG, Farndale RW: The collagen-platelet interaction. *Curr. Opin. Hematol.* 1998; 5:314-320
23. Andrews RK, Berndt MC: Adhesion-dependent signalling and the initiation of haemostasis and thrombosis. *Histol. Histopathol.* 1998; 13:837-844
24. Bellucci-Sessa S, Caen JP: Inherited platelet disorders; in Hoffbrand, A. V., Lewis, S. M., and Tuddenham, E. G. D. (ed): *Postgraduate Haematology*. Oxford, Butterworth Heinemann, 1999, pp. 581-596.
25. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I: Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. *Blood* 1996; 88:3-40
26. Coller BS, Springer KT, Beer JH, Mohandas N, Scudder LE, Norton KJ, West SM: Thromboerythrocytes. *In-vitro* studies of a potential autologous, semi-artificial alternative to platelet transfusions. *J. Clin. Invest.* 1992; 89:546-555
27. Porcelijn L, Folman CC, Bossers B, Huiskes E, Overbeeke MAM, van der Schoot CE, de Haas M, von dem Borne AEG Kr: The diagnostic value of thrombopoietin level measurements in thrombocytopenia. *Thrombos. Haemostas.* 1998; 79:1101-1105
28. Steffan A, Pradella P, Cordiano I, Girolami A, De Marco L, Fabris F: Glycocalicin in the diagnosis and management of immune thrombocytopenia. *Eur. J. Haematol.* 1998; 61:77-83
29. Kunishima S, Tahara T, Kato T, Kobayashi S, Saito H, Naoe T: Serum thrombopoietin and plasma glycocalicin concentrations as useful diagnostic markers in thrombocytopenic disorders. *Eur. J. Haematol.* 1996; 57:68-71
30. Pietersz RNI, de Korte D, Reesink HW, Dekker WJA, van den Ende A, Loos JA: Storage of whole blood for up to 24 h at ambient temperature prior to component preparation. *Vox Sang.* 1989; 56:145-150
31. de Korte D, Palfenier T, Pankalla-Blandeau I, Veldman HA, Loos JA: Minimal hemoglobin loss by buffy-coat removal with the new Compomat G4. *Nederl. Milit. Geneesk. T.* 1996; 49:57-96
32. Fijnheer R, Pietersz RNI, de Korte D, Gouwerok CWN, Dekker WJA, Reesink HW, Roos D: Platelet activation during preparation of platelet concentrates: A comparison of the platelet-rich plasma and the buffy coat methods. *Transfusion* 1990; 30:634-638

33. Heaton WA, Rebullia P, Pappalettera M, Dzik WH: A comparative analysis of different methods for routine blood component preparation. *Transf. Med. Rev.* 1997; 11:116-129
34. Murphy S, Heaton WA, Rebullia P: Platelet production in the Old World and the New. *Transfusion* 1996; 36:751-754
35. Pamphilon DH, Rider JR, Barbara JAJ, Williamson LM: Prevention of transfusion-transmitted cytomegalovirus infection. *Transfusion Med.* 1999; 9:115-123
36. van Prooijen HC, Visser JJ, Van Oostendorp WR, de Gast GC, Verdonck LF: Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. *Brit. J. Haematol.* 1994; 87:144-147
37. Bowden RA, Slichter SJ, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, *et al.*: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. *Blood* 1995; 86:3598-3603
38. Wagner SJ, Robinette D: Evaluation of swirling, pH, and glucose tests for the detection of bacterial contamination in platelet concentrates. *Transfusion* 1996; 36:989-993
39. Blajchman MA: Bacterial contamination of blood products and the value of pre-transfusion testing. *Immunol. Invest.* 1995; 24:163-170
40. Illert WE, Sanger W, Weise W: Bacterial contamination of single-donor blood components. *Transfus. Med.* 1995; 5:57-61
41. Alvarez FE, Rogge KJ, Tarrand J, Lichtiger B: Bacterial contamination of cellular blood components. A retrospective review at a large cancer center. *Ann. Clin. Lab. Sci.* 1995; 25:283-290
42. Barrett BB, Andersen JW, Anderson KC: Strategies for the avoidance of bacterial contamination of blood components. *Transfusion* 1993; 33:228-233
43. Morrow JF, Braine HG, Kickler TS, Ness PM, Dick JD, Fuller AK: Septic reactions to platelet transfusions. A persistent problem. *JAMA* 1991; 266:555-558
44. Dzieczkowski JS, Barrett BB, Nester D, Campbell M, Cook J, Sugrue M, Andersen JW, Anderson KC: Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. *Transfusion* 1995; 35:20-25
45. Klein MA, Frigg R, Flechsig E, Raeber AJ, Kalinke U, Bluethmann H, Bootz F, Suter M, Zinkernagel RM, Aguzzi A: A crucial role for B cells in neuroinvasive scrapie. *Nature* 1997; 390:687-690
46. Klein MA, Frigg R, Raeber AJ, Flechsig E, Hegyi I, Zinkernagel RM, Weissmann C, Aguzzi A: PrP expression in B lymphocytes is not required for prion neuroinvasion. *Nature Med.* 1998; 4:1369-1370
47. Mabbott NA, Farquhar CF, Brown KL, Bruce ME: Involvement of the immune system in TSE pathogenesis. *Immunol. Today* 1998; 19:201-203
48. Raeber AJ, Klein MA, Frigg R, Flechsig E, Aguzzi A, Weissmann C: PrP-dependent association of prions with splenic but not circulating lymphocytes of scrapie-infected mice. *EMBO J.* 1999; 18:2702-2706
49. Dodd RY: Transmission of parasites by blood transfusion. *Vox Sang.* 1998; 74 (Suppl. 2):161-163
50. Moraes-Souza H, Bordin JO, Bardossy L, MacPherson DW, Blajchman MA: Prevention of transfusion-associated Chagas' disease: Efficacy of white cell-

- reduction filters in removing *Trypanosoma cruzi* from infected blood. *Transfusion* 1995; 35:723-726
51. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME: Increased tumor necrosis factor α (TNF α), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: Relationship between TNF α and IL-6 levels and febrile transfusion reactions. *Transfusion* 1993; 33:195-199
 52. Muylle L, Peetermans ME: Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. *Vox Sang.* 1994; 66:14-17
 53. Heddle NM, Klama L, Singer J, Richards C, Fedak P, Walker I, Kelton JG: The role of the plasma from platelet concentrates in transfusion reactions. *New Engl. J. Med.* 1994; 331:625-628
 54. Novotny VMJ: Prevention and management of platelet transfusion refractoriness. *Vox Sang.* 1999; 76:1-13
 55. The trial to reduce alloimmunization to platelets study group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. *New Engl. J. Med.* 1997; 337:1861-1869
 56. Murphy MF: Clinical aspects of platelet transfusion therapy. *Infusionsther. Transfusionsmed.* 1994; 21(suppl.3):34-38
 57. Friedberg RC, Mintz PD: Causes of refractoriness to platelet transfusion. *Curr. Opin. Hematol.* 1995; 2:493-498
 58. Anderson NA, Gray S, Coppleston JA, Chan DC, Hamon M, Prentice AG, Johnson SAN, Phillips M, van Waeg G, Oakhill A, Abeyasekera S, Pamphilon DH: A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. *Transfusion Med.* 1996; 6:33-39
 59. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JWN: Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial. *Blood* 1991; 77:201-205
 60. Novotny VMJ, Van Doorn R, Witvliet MD, Claas FHJ, Brand A: Occurrence of allogeneic HLA- and non-HLA antibodies after transfusion of prestorage filtered platelet and red blood cells: A prospective study. *Blood* 1995; 85:1736-1741
 61. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC, van Dijk BA, van Puttem WLJ, Claas FHJ, Novotny VMJ, Brand A: Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. *Blood* 1995; 85:824-828
 62. Sweeney JD, Holme S, Heaton WAL, Nelson E: White cell-reduced platelet concentrates prepared by in-line filtration of platelet-rich plasma. *Transfusion* 1995; 35:131-136
 63. Dzik WH, Cusack WF, Gacek MJ: Preparation of white cell-reduced platelet concentrates from whole blood during component preparation. *Transfusion* 1991; 31:542-546
 64. Kickler TS, Bell W, Ness PM, Drew H, Pall D: Depletion of white cells from platelet concentrates with a new adsorption filter. *Transfusion* 1989; 29:411-414

65. van Marwijk Kooy M, van Prooijen HC, Borghuis L, Moes M, Akkerman JWN: Filtration. A method to prepare white cell-poor platelet concentrates with optimal preservation of platelet viability. *Transfusion* 1990; 30:34-38
66. Wadenvik H, Kutti J, Lindholm A: Leukocyte removal filtration of platelet concentrates. A study of platelet loss using ¹¹¹In-labelled platelets and dynamic gamma camera scintigraphy. *Eur. J. Haematol.* 1991; 47:192-196
67. Amiji M, Park K: Prevention of protein adsorption and platelet adhesion on surfaces by PEO/PPO/PEO triblock copolymers. *Biomaterials* 1992; 13:682-691
68. Bruil A, Brenneisen LM, Terlingen JGA, Beugeling T, van Aken WG, Feijen J: *In vitro* leukocyte adhesion to modified polyurethane surfaces II. Effect of wettability. *J. Colloid Interface Sci.* 1994; 165:72-81
69. Bruil A, Beugeling T, Feijen J, van Aken WG: The mechanisms of leukocyte removal by filtration. *Transfusion Med. Rev.* 1995; IX:145-166
70. Klomp AJA: Design of surface-modified poly(ethylene terephthalate) non-woven for leukocyte removal from platelet concentrates (PhD thesis). Enschede, University of Twente, 1998, pp 45-64
71. Amiji MM, Park K: Analysis on the surface adsorption of PEO/PPO/PEO triblock copolymers by radiolabelling and fluorescence techniques. *J. Appl. Polymer Sci.* 1994; 52:539-544
72. Yenicesu I, Teczan I, Tuncer AM: Hypotensive reactions during platelet transfusions. *Transfusion* 1998; 38:410-410
73. Sweeney JD, Dupuis M, Mega AJ: Hypotensive reactions to red cells filtered at the bedside but not to those filtered before storage, in patients taking ACE inhibitors. *Transfusion* 1998; 38:410-411
74. Abe H, Ikebuchi K, Shimbo M, Sekiguchi S: Hypotensive reactions with a white cell-reduction filter: activation of kallikrein-kinin cascade in a patient. *Transfusion* 1998; 38: 411-412
75. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. *Pharmacol. Rev.* 1980; 32:1-46
76. Hild M, Söderström T, Egberg N, Lundahl J: Kinetics of bradykinin levels during and after leucocyte filtration of platelet concentrates. *Vox Sang.* 1998; 75:18-25
77. Krailadsiri P, Seghatchian J: Negatively charged leucocyte filter significantly enhances kallikrein and thrombin-like activities of platelet concentrates. *Thromb. Res.* 1996; 83: 469-474
78. Shiba M, Tadokoro K, Nakajima K, Juji T: Bradykinin generation in RC-MAP during storage at 4°C and leukocyte removal filtration. *Thromb. Res.* 1997; 87:511-520
79. Novotny VMJ, Van Doorn R, Rozier Y, D'Amario J, Harvey MS, Brand A: Transfusion results of filtered and subsequently stored random platelet suspensions prepared from buffy coats. *Vox Sang.* 1992; 63:23-30
80. Norol F, Kuentz M, Cordonnier C, Beaujean F, Haioun C, Vernant JP, Duédari N: Influence of clinical status on the efficiency of stored platelet transfusion. *Brit. J. Haematol.* 1994; 86:125-129
81. Snyder EL: Activation during preparation and storage of platelet concentrates. *Transfusion* 1992; 32:500-502

82. Murphy S, Rebulli P, Bertolini F, Holme S, Moroff G, Snyder E, Stromberg R: *In-vitro* assessment of the quality of stored platelet concentrates. *Transfusion Med. Rev.* 1994; 8: 29-36
83. Prins HK, de Bruijn JCGH, Henrichs HPJ, Loos JA: Prevention of microaggregate formation by the removal of "buffycoats". *Vox Sang.* 1980; 39:48-51
84. Loos JA: Automation in blood component preparation; in Murawski, K. and Peetoom, F. (ed): *Transfusion Medicine Recent Technological Advances*. New York, Alan R. Liss, Inc, 1985, pp 333-341.
85. Pietersz RNI, Reesink HW, Dekker WJA, Fijen FJ: Preparation of leukocyte-poor platelet concentrates from buffy coats. I. Special inserts for centrifuge cups. *Vox Sang.* 1987; 53:203-207
86. Pietersz RNI, Dekker WJA, Reesink HW: Comparison of a conventional quadruple-bag system with a 'top-and-bottom' system for blood processing. *Vox Sang.* 1990; 59: 205-208
87. Pietersz RNI, Loos JA, Reesink HW: Platelet concentrates stored in plasma for 72 hours at 22°C prepared from buffy coats of citrate-phosphate-dextrose blood collected in a quadruple-bag saline-adenine-glucose-mannitol system. *Vox Sang.* 1985; 49:81-85
88. Council of Europe: Guide to the preparation, use and quality assurance of blood components. Strasbourg, Council of Europe, 1999
89. Loos JA, Wautier JL: Leukocyte depletion: a biotechnical transfusion story. *Transfusion Med. Rev.* 1998; 5:64-79
90. van Delden C.J., Faber RD, de Wit HJC, Smit Sibinga CTh: Leukocyte-poor platelet concentrate production via a hard short spin of a pool of buffy coats. *Transfusion* 1999; 37S:13S-13S
91. Eriksson L, Högman CF: Platelet concentrates in an additive solution prepared from pooled buffy coats. 1. *In-vitro* studies. *Vox Sang.* 1990; 59:140-145
92. Mrowiec ZR, Oleksowicz L, Dutcher JP, De Leon-Fernandez M, Lalezari P, Puszkin EG: A novel technique for preparing improved buffy-coat platelet concentrates. *Blood Cells, Molecules, and Diseases* 1995; 21:25-33
93. Snyder EL, DePalma L, Napychank P: Use of polyester filters for the preparation of leukocyte-poor platelet concentrates. *Vox Sang.* 1988; 54:21-23
94. Klomp AJA: Design of surface-modified poly(ethylene terephthalate) non-woven for leukocyte removal from platelet concentrates (PhD thesis). Enschede, University of Twente, 1998, pp 65-93
95. Klomp AJA: Design of surface-modified poly(ethylene terephthalate) non-woven for leukocyte removal from platelet concentrates (PhD thesis). Enschede, University of Twente, 1998, p 19
96. Klomp AJA: Design of surface-modified poly(ethylene terephthalate) non-woven for leukocyte removal from platelet concentrates (PhD thesis). Enschede, University of Twente, 1998, pp 95-111
97. Takens GAJ: Functionalization of polymeric surfaces by oxidative gas plasma treatment (Ph.D. thesis). Enschede, University of Twente, 1998, p 65
98. *Non-parametric Statistical Methods*, A Wiley Publication in Applied Statistics. New York, Wiley & Sons, 1973
99. Mood AM, Graybill FA, Boes DC: *Introduction to the theory of statistics*. McGraw Hill, 3, 1987

100. Elias-Elias MK, Smith JW, Weggemans M, Rijkskamp L, Carper H, McShine RL, Brons R, Pietens J, Halie MR, Smit-Sibinga CT: *In-vitro* evaluation of a high-efficiency leucocyte adherence filter. *Ann. Hematol.* 1991; 63:302-306
101. Andreu G, Dewailly J, Leberre C, Quarre MC, Bidet ML, Tardivel R, Devers L, Lam Y, Soreau E, Boccaccio C, Piard N, Bidet JM, Genetet B, Fauchet R: Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. *Blood* 1988; 72:964-969
102. Williamson LM, Wimperis JZ, Williamson P, Coplestone JA, Gooi HC, Morgenstern GR, Norfolk DR: Bedside filtration of blood products in the prevention of HLA alloimmunization - A prospective randomized study. *Blood* 1994; 83:3028-3035
103. Claas FHI, Smeenk RJT, Schmidt R, van Steenbrugge GJ, Eernisse JG: Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspensions. *J. Exp. Hematol.* 1981; 9:84-89
104. Slichter SJ, Harker LA: Preparation and storage of platelet concentrates. II. Storage variables influencing platelet viability and function. *Brit. J. Haematol.* 1976; 34:403-419
105. Boomgaard MN, Joustra-Dijkhuis AM, Gouwerok CWN, Steneker I, Reesink HW, Loos JA, Pietersz RNI, de Korte D: *In-vitro* evaluation of platelet concentrates, prepared from pooled buffy coats, stored for 8 days after filtration. *Transfusion* 1994; 34:311-316
106. Boomgaard MN, Gouwerok CWN, de Korte D, Loos JA: Platelets stored for 6 days in a polyolefin container in a synthetic medium with minimal plasma carry-over. *Vox Sang.* 1994; 66:18-24
107. Kunicki TJ, Tuccelli M, Becker GA, Aster RH: A study of the variables affecting the quality of platelets stored at room temperature. *Transfusion* 1975; 15:414-421
108. Boomgaard MN, Steneker I, Gouwerok CWN, Pietersz RNI, de Korte D, Loos JA: Platelet morphology during storage, a light-microscopical and electron-microscopical study; in *Quality Aspects of Platelet Concentrates for Transfusion Purposes*. Amsterdam, University of Amsterdam, 1994, vol 109-120.
109. Wells JI: Drug stability; in *Pharmaceutical Preformulation: the physicochemical properties of drug substances*. Chichester, Ellis Horwood Limited, 1988, vol 152-153.
110. Gennaro AR: Gennaro, A. R. (ed): *Remington's Pharmaceutical Sciences*. Easton, Pennsylvania, Mack Publishing Company, 1985, vol 252-252.
111. Steneker I, Van Luyn MJA, Van Wachem PB, Biewenga J: Electronmicroscopic examination of white cell reduction by four white cell-reduction filters. *Transfusion* 1992; 32: 450-457
112. Weisbach V, Putzo A, Zingsem J, Riewald M, Zimmermann R, Eckstein R, Riess H: Leukocyte depletion and storage of single-donor platelet concentrates. *Vox Sang.* 1997; 72: 20-25
113. Engbers GH, Feijen J: Current techniques to improve the blood compatibility of biomaterial surfaces. *Int. J. Artif. Organs.* 1991; 14:199-215
114. Iwasaki Y, Ishihara K, Nakabayashi N, Khang G, Jeon JH, Lee JW, Lee HB: Platelet adhesion on the gradient surfaces grafted with phospholipid polymer. *J. Biomater. Sci. Polymer Edn.* 1998; 9:801-816

115. van der Heiden AP, Willems GM, Lindhout T, Pijpers AP, Koole LH: Adsorption of proteins onto poly(ether urethane) with a phosphorylcholine moiety and influence of preadsorbed phospholipid. *J. Biomed. Mater. Res.* 1998; 40:195-203
116. Li Y-J, Nakaya T, Zhang Z, Kodama M: Blood compatible phospholipid-containing polyurethanes: synthesis, characterization and blood compatibility evaluation. *J. Biomat. Appl.* 1997; 12:167-191
117. Hayward JA, Chapman D: Biomembrane surfaces as models for polymer design: the potential for haemocompatibility. *Biomaterials* 1984; 5:135-142
118. Lee J, Martic PA, Tan JS: Protein adsorption on pluronic copolymer-coated polystyrene particles. *J. Colloid Interface Sci.* 1989; 131:525-265
119. Murphy S, Gardner FH: Platelet storage at 22°C: role of gas transport across plastic containers in maintenance of viability. *Blood* 1975; 46:209-218
120. Rock G, Tittley P, Sherring V, Culley G, Wong SC: Platelet storage: An assessment of the requirements of plasma and oxygen. *Transfusion* 1981; 21:167-177
121. Solberg C, Holme S, Little C: Morphological changes associated with pH changes during storage of platelet concentrates. *Beitr. Infusionther. Klin. Ernahr.* 1986; 15:107-117
122. Bannai M, Mazda T, Sasakawa S: The effects of pH and agitation on platelet preservation. *Transfusion* 1985; 25:57-59
123. Wallvik J, Akerblom O: Platelet concentrates stored at 22°C need oxygen: The significance of plastics in platelet preservation. *Vox Sang.* 1983; 45:303-311
124. Kakaiya RM, Katz AJ: Platelet preservation in large containers. *Vox Sang.* 1984; 46(2):111-118
125. Boomgaard MN, Gouwerok CWN, Palfenier CH, Pankalla-Blandeau IE, Veldman HA, de Korte D, Loos JA: Pooled platelet concentrates prepared by the platelet-rich plasma method, filtered by three different filters and stored for 8 days. *Vox Sang.* 1995; 68:82-89
126. Fratantoni JC, Poindexter BJ, Bonner RF: Quantitative assessment of platelet morphology by light scattering: a potential method for the evaluation of platelets for transfusion. *J. Lab. Clin. Med.* 1984; 102:620-631
127. de Korte D, Haverkort WA, Roos D, van Gennip AH: Anion-exchange high performance liquid chromatography method for the quantitation of nucleotides in human blood cells. *Clin. Chim. Acta* 1985; 148:185-196
128. van Gennip AH: Screening for inborn errors of purine and pyrimidine metabolism by dimensional TLC and HPLC; in Krstulovic, A. M. (ed): *Handbook of chromatography, nucleic acids and related compounds*. Boca Raton, CRC Press, 1987, vol 221-246.
129. Fijnheer R, Modderman PW, Veldman H, Ouwehand WH, Nieuwenhuis HK, Roos D, de Korte D: Detection of platelet activation with monoclonal antibodies and flowcytometry: changes during platelet storage. *Transfusion* 1990; 30:20-25
130. Dolhofer R: Experiences with the glucose-dehydrogenase UV method for the determination of blood glucose. *J. Clin. Chem. Clin. Biochem.* 1976; 4:415-417
131. Kostelijk EH, Fijnheer R, Nieuwenhuis HK, Gouwerok CWN, de Korte D: Soluble P-selectin as parameter for platelet activation during storage. *Thrombos. Haemostas.* 1996; 76: 1086-1089
132. Holm S: Simple sequentially rejective multiple test procedure. *Scand. J. Statistics* 1979; 6:65-70

133. Joustra-Dijkhuis AM, Boomgaard MN, Pietersz RNI, Steneker I, de Korte D, Loos JA, Reesink HW: Effect of filtration on subsequently stored platelet concentrates. *Vox Sang.* 1994; 67:22-27
134. de Korte D, Gouwerok CWN, Fijnheer R, Pietersz RNI, Roos D: Depletion of dense granule nucleotides during storage of human platelets. *Thrombos. Haemostas.* 1990; 63: 275-278
135. Shimizu T, Mizuno S, Yamaguchi H, Kamiya T, Kokubo Y: Filtration through a polyester white cell-reduction filter of plasma-poor platelet concentrates prepared with an acetate-containing additive solution. *Transfusion* 1993; 33:730-734
136. Rinder HM, Snyder EL: Activation of platelet concentrates during preparation and storage. *Blood Cells* 1992; 18:445-456
137. Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B: A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. *J. Clin. Invest.* 1986; 78:130-137
138. Cramer EM, Berger G, Berndt MC: Platelet α -granule and plasma membrane share two new components: CD9 and PECAM-1. *Blood* 1994; 84:1722-1730
139. Johnston GI, Bliss GA, Newman PJ, McEver RP: Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes. *J. Biol. Chem.* 1990; 265:21381-21385
140. Hamburger SA, McEver RP: GMP-140 mediates adhesion of stimulated platelets to neutrophils. *Blood* 1990; 75:550-554
141. McEver RP: GMP-140: A receptor for neutrophils and monocytes on activated platelets and endothelium. *J. Cell. Biochem.* 1991; 45:156-161
142. Ishiwata N, Takio K, Katayama M, Watanabe K, Titani K, Ikeda Y, Handa M: Alternatively spliced isoform of P-selectin is present *in vivo* as a soluble molecule. *J. Biol. Chem.* 1994; 269:23708-23715
143. Dunlop LC, Skinner MP, Bendall LJ, Favalaro EJ, Castaldi PA, Gorman JJ, Gamble JR, Vadas MA, Berndt MC: Characterization of GMP-140 (P-selectin) as a circulating plasma protein. *J. Exp. Med.* 1992; 175:1147-1150
144. Katayama M, Handa M, Ambo H, Araki Y, Hirai S, Kato I, Kawai Y, Watanabe K, Ikeda Y: A monoclonal antibody-based enzyme immunoassay for human GMP-140/P-selectin. *J. Immunol. Methods* 1992; 153:41-48
145. Rinder HM, Snyder EL, Bonan JL, Napychank PA, Malkus H, Smith BR: Activation in stored platelet concentrates: correlation between membrane expression of P-selectin, glycoprotein IIb/IIIa, and beta-thromboglobulin release. *Transfusion* 1993; 33:25-29
146. Divers SG, Kannan K, Stewart RM, Betzing KW, Dempsey D, Fukuda M, Chervenak R, Holcombe RF: Quantitation of CD62, soluble CD62, lysosome-associated membrane proteins 1 and 2 for evaluation of quality of stored platelet concentrates. *Transfusion* 1995; 35:292-297
147. Wagner DD: P-selectin chases a butterfly. *J. Clin. Invest.* 1995; 95:1955-1956
148. Stoolman LM: Adhesion molecules controlling lymphocyte migration. *Cell* 1989; 56:907-910
149. Goldberger A, Middleton KA, Oliver JA, Paddock C, Y H-C, Delisser HM, Albeda SM, Newman PJ: Biosynthesis and processing of the cell adhesion molecule PECAM- 1 includes production of a soluble form. *J. Biol. Chem.* 1994; 269:17183-17191

150. Beer JH, Büchi L, Steiner B: Glycocalicin: a new assay-the normal plasma levels and its potential usefulness in selected diseases. *Blood* 1994; 83:691-702
151. Bessos H, Murphy WG: A new competitive binding enzyme-linked immuno-sorbent assay for glycocalicin in plasma and platelet concentrate supernatants. *Thromb. Res.* 1990; 59:497-507
152. Bessos H, Murphy WG, Seghatchian MJ: Monitoring the release of glycocalicin in platelet concentrates by ELISA. *Blood Coagulation and Fibrinolysis* 1991; 2:373-376
153. Kunishima S, Hayashi K, Kobayashi S, Naoe T, Ohno R: New enzyme-linked immunosorbent assay for glycocalicin in plasma. *Clin. Chem.* 1991; 37:169-172
154. Bessos H, Seghatchian MJ, Cutts M, Murphy WG: Glycoproteins Ib and IIb/IIIa in the quality assessment of platelet concentrates during storage. *Blood Coagulation and Fibrinolysis* 1992; 3:633-636
155. George JN, Thoi LL, McManus LM, Reimann TA: Isolation of human platelet membrane microparticles from plasma and serum. *Blood* 1982; 60:834-840
156. Bode AP, Orton SM, Frye MJ, Udis BJ: Vesiculation of platelets during *in-vitro* aging. *Blood* 1991; 77:887-895
157. George JN, Pickett EB, Heinz R: Platelet membrane glycoprotein changes during the preparation and storage of platelet concentrates. *Transfusion* 1988; 28:123-126
158. Kunishima S, Shimizu T, Kora S, Kamiya T, Ozawa K: Determination of glycocalicin in platelet concentrate supernatants stored in a synthetic medium (Seto solution). *Vox Sang.* 1998; 75:74-75
159. Loscalzo J, Handin RI: Platelet glycocalicin. *Methods Enzymol.* 1992; 215:289-294
160. Halim A, Kanayama N, El Maradny E, Nakashima A, Bhuiyan AB, Khatun S, Terao T: Plasma P selectin (GMP-140) and glycocalicin are elevated in pre-eclampsia and eclampsia: Their significances. *Am. J. Obstet. Gynecol.* 1996; 174:272-277